Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
35.22
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Jun 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
November 16, 2023
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small
Via
Benzinga
Exposures
Product Safety
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
November 14, 2023
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END
Via
FinancialNewsMedia
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
November 10, 2023
The real competitive battle is about to begin, and it will last a long time.
Via
The Motley Fool
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
November 07, 2023
The company's recently FDA-approved gene therapy is struggling to gain traction.
Via
Investor's Business Daily
Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug
November 02, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate
Via
Benzinga
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
October 31, 2023
Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)...
Via
Benzinga
Exposures
Product Safety
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
October 28, 2023
The U.S.
Via
Benzinga
Exposures
Product Safety
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
October 28, 2023
The three companies are spending big on IBD therapies.
Via
The Motley Fool
FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
October 27, 2023
From
Genentech
Via
Business Wire
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy
October 24, 2023
The market's dour reaction to Roivant Sciences' latest deal doesn't add up.
Via
The Motley Fool
Why Is Roivant Sciences (ROIV) Stock Up Today?
October 23, 2023
ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates.
Via
InvestorPlace
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise
October 23, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
October 23, 2023
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases.
Via
Investor's Business Daily
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal
October 23, 2023
Roche Holding AG (OTC: RHHBY) inked a deal to acquire
Via
Benzinga
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
October 23, 2023
From
Roivant Sciences
Via
GlobeNewswire
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
October 21, 2023
The venerable pharmaceutical companies' shares have slumped this year.
Via
The Motley Fool
Drug Giant Roche Skids As Covid Products Decline Weighs On Sales, Guidance
October 19, 2023
The company's third-quarter sales also declined and came in light.
Via
Investor's Business Daily
Exposures
COVID-19
Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products
October 19, 2023
Roche Holdings AG's (OTC: RHHBY) nine months
Via
Benzinga
Exposures
COVID-19
Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer
October 18, 2023
From
Genentech
Via
Business Wire
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?
October 17, 2023
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC:
Via
Benzinga
FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication
October 17, 2023
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing...
Via
Benzinga
Exposures
Product Safety
Why Is Alzheimer's Player Prothena Stock Trading Higher Today?
October 16, 2023
Prothena Corporation plc (NASDAQ: PRTA) is reportedly talking to advisors, potentially preparing for a sale.
Via
Benzinga
AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points
October 14, 2023
Broadcom and Arista lead five stocks sporting a flat base.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Late-Breaking Data for Genentech’s BTK Inhibitor Fenebrutinib Show Brain Penetration and Significant Reduction in Lesions in Patients With Relapsing Multiple Sclerosis
October 13, 2023
From
Genentech
Via
Business Wire
New Data for Genentech’s Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk Unaided
October 12, 2023
From
Genentech
Via
Business Wire
TPST Stock: 7 Things to Know About Tempest Therapeutics
October 11, 2023
Are you curious about the recent surge from Tempest Therapeutics? Here's a closer look at this company and at TPST stock.
Via
InvestorPlace
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
October 11, 2023
Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are...
Via
Benzinga
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
October 11, 2023
From
Genentech
Via
Business Wire
First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity
October 11, 2023
From
Genentech
Via
Business Wire
Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials
October 10, 2023
From
Genentech
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.